Featured Publications
Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis
Barmada A, Klein J, Ramaswamy A, Brodsky N, Jaycox J, Sheikha H, Jones K, Habet V, Campbell M, Sumida T, Kontorovich A, Bogunovic D, Oliveira C, Steele J, Hall E, Pena-Hernandez M, Monteiro V, Lucas C, Ring A, Omer S, Iwasaki A, Yildirim I, Lucas C. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. Science Immunology 2023, 8: eadh3455-eadh3455. PMID: 37146127, PMCID: PMC10468758, DOI: 10.1126/sciimmunol.adh3455.Peer-Reviewed Original ResearchConceptsMRNA vaccinesSARS-CoV-2 mRNA vaccinesSARS-CoV-2 mRNA vaccinationC-reactive protein levelsB-type natriuretic peptidePeripheral blood mononuclear cellsCardiac tissue inflammationDeep immune profilingSerum soluble CD163Vaccine-associated myocarditisCohort of patientsBlood mononuclear cellsCytotoxic T cellsLate gadolinium enhancementHypersensitivity myocarditisElevated troponinMRNA vaccinationImaging abnormalitiesNK cellsImmune profilingKiller cellsMyeloid responseNatriuretic peptideHumoral mechanismsInflammatory cytokinesSafety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial.
El Sahly HM, Yildirim I, Frey SE, Winokur P, Jackson LA, Bernstein DI, Creech CB, Chen WH, Rupp RE, Whitaker JA, Phadke V, Hoft DF, Ince D, Brady RC, Edwards KM, Ortiz JR, Berman MA, Weiss J, Wegel A, DMID 17-0090 Study Group. Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. J Infect Dis 2023 PMID: 37466221, DOI: 10.1093/infdis/jiad276.Peer-Reviewed Original ResearchSARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox J, Lucas C, Yildirim I, Dai Y, Wang E, Monteiro V, Lord S, Carlin J, Kita M, Buckner J, Ma S, Campbell M, Ko A, Omer S, Lucas C, Speake C, Iwasaki A, Ring A. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nature Communications 2023, 14: 1299. PMID: 36894554, PMCID: PMC9996559, DOI: 10.1038/s41467-023-36686-8.Peer-Reviewed Original ResearchConceptsVaccine-associated myocarditisAutoimmune patientsAutoantibody reactivitySARS-CoV-2 mRNA vaccinationVaccine-related adverse effectsSARS-CoV-2 immunitySARS-CoV-2 infectionAcute COVID-19Development of autoantibodiesCOVID-19 patientsAnti-viral immunityVirus-specific antibodiesCOVID-19 vaccineCOVID-19Humoral autoimmunityMRNA vaccinationAutoantibody responsePost vaccinationAutoantibody developmentAutoimmune diseasesHumoral responseHealthy individualsPatientsAntigen profilingAdverse effectsNonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants
Petrone M, Lucas C, Menasche B, Breban M, Yildirim I, Campbell M, Omer S, Holmes E, Ko A, Grubaugh N, Iwasaki A, Wilen C, Vogels C, Fauver J. Nonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants. Genome Biology And Evolution 2023, 15: evad052. PMID: 36974986, PMCID: PMC10113931, DOI: 10.1093/gbe/evad052.Peer-Reviewed Original ResearchBivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Duron Padilla M, Richmond PC, Koury K, Schneider K, Kalinina EV, Cooper D, Jansen KU, Anderson AS, Swanson KA, Gruber WC, Gurtman A, MATISSE Study Group. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med 2023, 388: 1451-1464. PMID: 37018474, DOI: 10.1056/NEJMoa2216480.Peer-Reviewed Original ResearchEvidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Lind M, Dorion M, Houde A, Lansing M, Lapidus S, Thomas R, Yildirim I, Omer S, Schulz W, Andrews J, Hitchings M, Kennedy B, Richeson R, Cummings D, Ko A. Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population. Nature Communications 2023, 14: 5055. PMID: 37598213, PMCID: PMC10439918, DOI: 10.1038/s41467-023-40750-8.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionPrior infectionHybrid immunityInfection riskCOVID-19 vaccinationNon-pharmaceutical interventionsInfected residentsVaccinationInfectionDocumented exposureDelta periodCell exposureIncarcerated populationsExposureImmunityRiskAssociationPotential benefitsCorrectional facilitiesCrowded settingsResidentsPeriodAdjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice from a Multicenter Cohort Study Conducted by the Pediatric Fungal Network.
Wattier RL, Bucayu RFT, Boge CLK, Ross RK, Yildirim I, Zaoutis TE, Palazzi DL, Vora SB, Castagnola E, Avilés-Robles M, Danziger-Isakov L, Tribble AC, Sharma TS, Arrieta AC, Maron G, Berman DM, Yin DE, Sung L, Green M, Roilides E, Belani K, Romero J, Soler-Palacin P, López-Medina E, Nolt D, Bin Hussain IZ, Muller WJ, Hauger SB, Halasa N, Dulek D, Pong A, Gonzalez BE, Abzug MJ, Carlesse F, Huppler AR, Rajan S, Aftandilian C, Ardura MI, Chakrabarti A, Hanisch B, Salvatore CM, Klingspor L, Knackstedt ED, Lutsar I, Santolaya ME, Shuster S, Johnson SK, Steinbach WJ, Fisher BT. Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice from a Multicenter Cohort Study Conducted by the Pediatric Fungal Network. J Pediatric Infect Dis Soc 2023 PMID: 37589394, DOI: 10.1093/jpids/piad057.Peer-Reviewed Original ResearchPneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
Adamkiewicz T, Yee M, Thomas S, Tunali A, Lai K, Omole F, Lane P, Yildirim I. Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines. Blood Advances 2023, 7: 6751-6761. PMID: 37698500, PMCID: PMC10660014, DOI: 10.1182/bloodadvances.2022009643.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSickle cell diseaseCell diseasePCV13-serotype invasive pneumococcal diseaseSerotype invasive pneumococcal diseaseNon-PCV13 serotypesPneumococcal polysaccharide vaccinePneumococcal conjugate vaccineIncidence rate ratiosYears of vaccinationReference populationLife-threatening risksIPD episodesIPD serotypesPneumococcal diseasePneumococcal infectionPolysaccharide vaccineConjugate vaccineHemoglobin SSVaccine licensureEffective vaccinePenicillin resistanceDisease controlVaccineAfrican American childrenDistinguishing features of long COVID identified through immune profiling
Klein J, Wood J, Jaycox J, Dhodapkar R, Lu P, Gehlhausen J, Tabachnikova A, Greene K, Tabacof L, Malik A, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott I, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng T, Xu L, Geraghty A, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick J, Kaminski N, Omer S, Krumholz H, Guan L, Dela Cruz C, van Dijk D, Ring A, Putrino D, Iwasaki A. Distinguishing features of long COVID identified through immune profiling. Nature 2023, 623: 139-148. PMID: 37748514, PMCID: PMC10620090, DOI: 10.1038/s41586-023-06651-y.Peer-Reviewed Original ResearchConceptsLong COVIDSARS-CoV-2Infection syndromeExaggerated humoral responseSoluble immune mediatorsEpstein-Barr virusPost-exertional malaiseCross-sectional studyHigher antibody responseImmune mediatorsImmune phenotypingImmune profilingHumoral responseAntibody responseLymphocyte populationsCOVID statusUnbiased machineCortisol levelsLC statusRelevant biomarkersViral pathogensSyndromeCOVIDFuture studiesBiological featuresEnvironmental surveillance for COVID-19 using SARS-CoV-2 RNA concentration in wastewater – a study in District East, Karachi, Pakistan
Ansari N, Kabir F, Khan W, Khalid F, Malik A, Warren J, Mehmood U, Kazi A, Yildirim I, Tanner W, Kalimuddin H, Kanwar S, Aziz F, Memon A, Alam M, Ikram A, Meschke J, Jehan F, Omer S, Nisar M. Environmental surveillance for COVID-19 using SARS-CoV-2 RNA concentration in wastewater – a study in District East, Karachi, Pakistan. The Lancet Regional Health - Southeast Asia 2023, 20: 100299. PMID: 38234701, PMCID: PMC10794106, DOI: 10.1016/j.lansea.2023.100299.Peer-Reviewed Original ResearchInvasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use.
Yildirim I, Lapidot R, Shaik-Dasthagirisaheb Y, Hinderstein S, Lee H, Klevens M, Grant L, Arguedas Mohs A, Cane A, Madoff L, Johnson H, Ivanof C, Burns M, Pelton S. Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use. Pediatrics 2023, 153 PMID: 38087952, DOI: 10.1542/peds.2023-063039.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseIPD casesPCV13 eraPneumococcal diseaseCases of IPDIncidence of IPDRates of IPDPneumococcal conjugate vaccine useSerotype 15B/CImplementation of PCV13Non-PCV13 serotypesPneumococcal conjugate vaccineConfidence intervalsStatewide surveillance systemIPD incidence ratesIPD ratesPenicillin nonsusceptibilityConjugate vaccineVaccine serotypesSerotype 19ASterile sitesIncidence rateVaccine useLower incidenceVaccine formulationsEvaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, Finkelstein D, Pickrell P, Kirstein J, Yut C, Blair R, Clifford RA, Dunn M, Campbell JD, Montefiori DC, Tomassini JE, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee R, Pajon R, Das R, Miller JM, Schnyder Ghamloush S. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. The New England Journal Of Medicine 2022, 386: 2011-2023. PMID: 35544369, PMCID: PMC9127699, DOI: 10.1056/NEJMoa2203315.Peer-Reviewed Original ResearchRelationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study
Patel KM, Shafiq M, Malik AA, Cobanoglu A, Klotz M, Eric Humphries J, Lee A, Murray T, Wilkinson D, Yildirim I, Elharake JA, Diaz R, Rojas R, Kuperwajs Cohen A, Omer SB, Gilliam WS. Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study. Vaccine 2022, 40: 4098-4104. PMID: 35660329, PMCID: PMC9135692, DOI: 10.1016/j.vaccine.2022.05.064.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationProspective cohort studyCare providersNonpharmaceutical interventionsChild care providersCohort studyLikelihood of vaccinationPreventative health behaviorsVaccinationHealth behaviorsCare programMandatory vaccinationSignificant associationVaccine mandatesDistrict of ColumbiaLarge healthInterventionPandemic controlCOVID-19Child care programsProvidersEmail surveyNonadherenceMeasuresCat Scratch Disease: 9 Years of Experience at a Pediatric Center
Amin O, Rostad CA, Gonzalez M, Rostad BS, Caltharp S, Quincer E, Betke BA, Gottdenker NL, Wilson JJ, Shane AL, Elmontser M, Camacho-Gonzalez A, Senior T, Smith O, Anderson EJ, Yildirim I. Cat Scratch Disease: 9 Years of Experience at a Pediatric Center. Open Forum Infectious Diseases 2022, 9: ofac426. PMID: 36072697, PMCID: PMC9439574, DOI: 10.1093/ofid/ofac426.Peer-Reviewed Original ResearchCat-scratch diseaseClinical featuresAtypical clinical manifestationsPediatric hospital systemMajority of casesPediatric centersAtypical presentationCanine exposureCat exposureMedian ageRegional lymphadenopathyClinical manifestationsHepatic microabscessesPhysical examinationScratch diseaseMedical recordsPolymerase chain reactionRisk factorsSchool-aged childrenRetrospective analysisCytopathological resultsPatient careLymphadenopathyRadiographic imagingHospital systemFactors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers
Aguolu OG, Willebrand K, Elharake JA, Qureshi HM, Kiti MC, Liu CY, Mesa A, Nelson K, Jenness S, Melegaro A, Ahmed F, Yildirim I, Malik FA, Lopman B, Omer SB. Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers. Human Vaccines & Immunotherapeutics 2022, 18: 2122379. PMID: 36136345, PMCID: PMC9746537, DOI: 10.1080/21645515.2022.2122379.Peer-Reviewed Original ResearchConceptsInfluenza vaccinationNon-healthcare workersInfluenza vaccinePromotion messagesWorkplace vaccination programsSeasonal influenza vaccinationInfluenza vaccine acceptancePublic health authoritiesLogistic regression modelsInfluenza seasonPhysician recommendationVaccination acceptanceVaccine accessibilityVaccine acceptanceSevere outcomesVaccination programPromotion interventionsUS adultsWork absenceVaccinationVaccination decisionsHealth authoritiesSignificant mortalityUnderstanding predictorsSignificant predictorsEvaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
Anderson EJ, Creech CB, Berthaud V, Piramzadian A, Johnson KA, Zervos M, Garner F, Griffin C, Palanpurwala K, Turner M, Gerber J, Bennett RL, Ali K, Ampajwala M, Berman G, Nayak J, Chronis C, Rizzardi B, Muller WJ, Smith CA, Fuchs G, Hsia D, Tomassini JE, DeLucia D, Reuter C, Kuter B, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee R, Pajon R, Aunins A, Das R, Miller JM, Schnyder Ghamloush S, KidCOVE Study Group. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. N Engl J Med 2022, 387: 1673-1687. PMID: 36260859, DOI: 10.1056/NEJMoa2209367.Peer-Reviewed Original ResearchPrevalence of Chronic Diseases, Depression, and Stress Among US Childcare Professionals During the COVID-19 Pandemic
Elharake JA, Shafiq M, Cobanoglu A, Malik AA, Klotz M, Humphries JE, Murray T, Patel KM, Wilkinson D, Yildirim I, Diaz R, Rojas R, Cohen A, Lee A, Omer SB, Gilliam WS. Prevalence of Chronic Diseases, Depression, and Stress Among US Childcare Professionals During the COVID-19 Pandemic. Preventing Chronic Disease 2022, 19: e61. PMID: 36137183, PMCID: PMC9541678, DOI: 10.5888/pcd19.220132.Peer-Reviewed Original ResearchConceptsPhysical health conditionsMental healthHealth conditionsChronic diseasesDepression ratesCOVID-19 pandemicSex/gender disparityPublic health officialsChildcare professionalsSevere asthmaHeart diseaseUS adultsAsthma ratesSociodemographic characteristicsHealth officialsDepressionDiseaseNational representativenessLinear regression modelsPrevalenceHealthRegression modelsPandemicProfessionalsGender disparitiesAssessing the effectiveness of COVID-19 vaccines in Pakistan: A test-negative case-control study
Nisar M, Ansari N, Malik A, Shahid S, Lalani K, Chandna M, Younus A, Hasan Z, Khan U, Khalid F, Mahesar M, Farrukh Qazi M, Yildirim I, Jehan F, Omer S. Assessing the effectiveness of COVID-19 vaccines in Pakistan: A test-negative case-control study. Journal Of Infection 2023, 86: e144-e147. PMID: 36708775, PMCID: PMC9876011, DOI: 10.1016/j.jinf.2023.01.016.Peer-Reviewed Original ResearchCOVID-19 Vaccine Acceptance and Hesitancy Among Health Care Workers in Lebanon
Youssef N, Tfaily N, Moumneh M, Boutros C, Elharake J, Malik A, McFadden S, Galal B, Yildirim I, Khoshnood K, Omer S, Memish Z, Dbaibo G. COVID-19 Vaccine Acceptance and Hesitancy Among Health Care Workers in Lebanon. Journal Of Epidemiology And Global Health 2023, 13: 55-66. PMID: 36735184, PMCID: PMC9896451, DOI: 10.1007/s44197-023-00086-4.Peer-Reviewed Original ResearchConceptsHealth care workersCOVID-19 vaccine acceptanceVaccine acceptancePrevious infectionCare workersPrevious SARS-CoV-2 infectionSARS-CoV-2 infectionMethodsA cross-sectional studyCOVID-19 vaccination ratesCOVID-19 vaccinationCross-sectional studyCOVID-19 vaccineHealth care authoritiesVaccine uptakeVaccination ratesOrder of PhysiciansVaccine hesitancyGeneral populationHealthcare providersVaccineCare authoritiesInfectionCOVID-19 informationTrusted sourceCOVID-19 pandemicGlobal impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis.
Bennett JC, Deloria Knoll M, Kagucia EW, Garcia Quesada M, Zeger SL, Hetrich MK, Yang Y, Herbert C, Ogyu A, Cohen AL, Yildirim I, Winje BA, von Gottberg A, Viriot D, van der Linden M, Valentiner-Branth P, Suga S, Steens A, Skoczynska A, Sinkovec Zorko N, Scott JA, Savulescu C, Savrasova L, Sanz JC, Russell F, Ricketson LJ, Puentes R, Nuorti JP, Mereckiene J, McMahon K, McGeer A, Mad'arová L, Mackenzie GA, MacDonald L, Lepp T, Ladhani SN, Kristinsson KG, Kozakova J, Klein NP, Jayasinghe S, Ho PL, Hilty M, Heyderman RS, Hasanuzzaman M, Hammitt LL, Guevara M, Grgic-Vitek M, Gierke R, Georgakopoulou T, Galloway Y, Diawara I, Desmet S, De Wals P, Dagan R, Colzani E, Cohen C, Ciruela P, Chuluunbat U, Chan G, Camilli R, Bruce MG, Brandileone MC, Bigogo G, Ampofo K, O'Brien KL, Feikin DR, Hayford K, PSERENADE Team. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis 2024 PMID: 39706204, DOI: 10.1016/S1473-3099(24)00665-0.Peer-Reviewed Original Research